Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

Despite innovative pipeline assets, Regeneron's stock recovery above $1,000 is unlikely due to Eylea's revenue decline and lack of blockbuster drugs. The Pharma is fairly priced today, in my view.

Drug developer Regeneron Pharmaceuticals Inc. purchased the Pitney Bowes Inc. building at 1 Global View in Rensselaer Technology Park for $17.75 million, Pyramid Brokerage broker Peter Struzzi ...

Regeneron (NASDAQ:REGN) continued to earn bullish views on Wall Street on Friday after ... $4B and estimates ~$19.2B as the treatment's peak global sales potential. Citing an effect on non-smokers ...

To help address the impact of COPD on patients and communities, global healthcare companies Sanofi and Regeneron are working together to study the ripple effects of COPD and to help create a ...

Country Manager (Oncology), Regeneron Canada; Justin Holko, Senior Vice President, Global Oncology/Hematology Commercial Business Unit, Regeneron; Acher Elfassy, Country Manager (Immunology ...

In an interview with Pharm Exec Associate Editor Don Tracy, Karen Rodriguez-Lorenc, Global Program Head of Linvoseltamab, Regeneron talks about the possibility of linvoseltamab becoming a frontline ...

JERUSALEM & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today a global 1 agreement to ...

“This major collaboration with Roche provides important scale and global expertise to bring REGN-COV2 to many more patients in the United States and around the globe.” Regeneron and Roche will ...